Name: P01I0308P Human Interleukin 2 (IL2) Protein, Recombinant
Brand: Shanghai BlueGene Biotech CO., LTD.
Price: 100 USD

BlueGene Biotech P01I0308P Human Interleukin 2 (IL2) Protein, Recombinant

Immunology

Interleukin 2 (IL2) can also be called IL-2; TCGF; lymphokine.

Products

Specifications of P01I0308P Human Interleukin 2 (IL2) Protein, Recombinant

Product Information
catalog number	P01I0308P
Package Size	10ug/50ug/500ug/1mg
Other Names	IL-2; TCGF; lymphokine
Protein & NCBI Number	P60568, NM_000586.4
Host	E.coli
Express Region	Ala21-Thr153
Protein Sequence	APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEE VLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
Molecular Weight	The protein consists of 133 amino acids, with a predicted molecular weight of 15.4kDa, and the actual molecular weight is 13kDa.
Fusion Tag	None
Purity	≥90% SDS-PAGE
Physical Property	Liquid
Components	0.01M PBS+20% glycerol, sterile solution
Storage & Stability	After aliquoting, the stability of the samples can be maintained for up to 6 months at -20°C to -80°C, avoiding repeated freeze-thaw cycles.
Applications	Antibody preparation, immunoassay (ELISA, WB), subcellular localization and interaction protein identification, etc.
Lead Time	5 to 10 business days; 2 to 3 days for stock products

Background

Interleukin-2 (IL-2) exerts both immunosuppressive and immunostimulatory effects on cytotoxic effector cells by activating regulatory T cells (Tregs). These IL-2-mediated effects
depend on distinct expression patterns of IL-2 receptors (IL-2R): CD8+T cells and natural killer (NK) cells express high levels of the dimeric IL-2Rβ(CD122) and IL-2Rγ(γc) chains, while

Treg cells express high levels of IL-2Rα(CD25) along with intermediate levels of CD122 and γc.

IL-2 was the first cytokine to be molecularly cloned and is an essential T cell growth factor, required for T cell proliferation, effector cell generation, and memory cell development. IL-2 supports the development, survival, and functional activity of Treg cells, thereby exerting dual and opposing roles: maintain Treg cells to suppress immune responses while activating conventional T cells to promote immune responses..

Studies have demonstrated that certain IL-2 conformations preferentially target Treg cells by increasing dependency on CD25 binding while reducing interaction with CD122. Recent therapeutic strategies have emerged that utilize IL-2, IL-2 monoclonal antibodies, or IL-2 variants to enhance the number and function of Treg cell for the treatment of autoimmune diseases, while simultaneously addressing the ongoing challenge of minimizing the activation of effector T cells, memory T cells, NK cells, and other innate lymphoid cell populations.